摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6-fluoro-1-(3-pyridyl)-1,2,3,4-tetrahydroisoquinolin-3-one | 103913-51-5

中文名称
——
中文别名
——
英文名称
6-fluoro-1-(3-pyridyl)-1,2,3,4-tetrahydroisoquinolin-3-one
英文别名
6-Fluoro-1-(3'-pyridyl)-1,4-dihydro-isoquinol-3-one;6-fluoro-1-pyridin-3-yl-2,4-dihydro-1H-isoquinolin-3-one
6-fluoro-1-(3-pyridyl)-1,2,3,4-tetrahydroisoquinolin-3-one化学式
CAS
103913-51-5
化学式
C14H11FN2O
mdl
——
分子量
242.253
InChiKey
KYJYGJZOIVETNF-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.4
  • 重原子数:
    18
  • 可旋转键数:
    1
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.14
  • 拓扑面积:
    42
  • 氢给体数:
    1
  • 氢受体数:
    3

反应信息

点击查看最新优质反应信息

文献信息

  • Dihydroisoquinoline derivatives, process for their preparation and pharmaceutical compositions containing them
    申请人:BEECHAM GROUP PLC
    公开号:EP0183369A2
    公开(公告)日:1986-06-04
    Compounds of the general formula I in which: R, and R2 are independently hydrogen, C, 6 alkyl ortogether are a group X which is C3 6 polymethylene optionally in which one carbon atom is replaced by O, S or NR6 wherein R6 is hydrogen or C1 6 alkyl; R3 is a mono- or fused bi-cyclic heteroaromatic group having up to ten atoms in the aromatic ring(s), not more than four of which are selected from nitrogen, oxygen or sulphur, optionally C-substituted by one or more substituents selected from halogen, CF3, nitro, C1-6 alkoxy, C1-6 alkylthio, C2-7 alkanoyl or cyano; or is phenyl or naphthyl, optionally substituted by one or more substituents selected from halogen, CF3, nitro, C1-6 alkyl, C1 6 alkoxy, C1 6 alkylthio, C2-7 alkanoyl, carboxyl, C1-6 alkoxycarbonyl, cyano, CONR7R8 wherein R7 and R8 are selected from hydrogen or C1-6 alkyl or together are a group X; NR9 R10 wherein R9 and R10 are selected from hydrogen, C1-6 alkyl, C2-7 alkanoyl or C1-6 alkylsulphonyl or together are a group X; SO2NR11R12 wherein R11 and R12 are selected from hydrogen or C1-6 alkyl or together are a group X; or S(O)mR13 wherein m is 1 or 2 and R13 is C1-6 alkyl; Z is naphthyl or a mono- or fused bycyclic heteroaromatic ring having up to ten atoms in the aromatic ring(s), not more than four of which are selected from nitrogen, oxygen or sulphur or (when R3 is an optionally substituted naphthyl or heteroaromatic group as defined) Z is a phyenyl ring; and Z is optionally C-substituted by one or two substituents R4 and R5 which are independently selected from C1-6 alkyl, cyano, amino, aminocarbonyl or aminocarbamoyl optionally substituted by one or two C1-6 alkyl groups or by a group X, halogen, CF3, nitro, C1-6 alkoxy, C1-6 alkylthio, C2-7 alkanoyloxy or hydroxy, or together on adjacent carbon atoms are methylenedioxy or C3-5 polymethylene, are disclosed as an active therapeutic substances for the treatment of inflammatory conditions.
    通式 I 的化合物 其中 R 和 R2 独立地为氢、C, 6 烷基或共同为基团 X,该基团为 C3 6 聚亚甲基,其中一个碳原子可选地被 O、S 或 NR6 取代,其中 R6 为氢或 C1 6 烷基; R3 是单环或融合双环杂芳香族基团,在芳香环中最多有 10 个原子,其中不超过 4 个原子选自氮、氧或硫,可选择被一个或多个选自卤素、CF3、硝基、C1-6 烷氧基、C1-6 烷硫基、C2-7 烷酰基或氰基的取代基取代;或苯基或萘基,任选被一个或多个选自卤素、CF3、硝基、C1-6 烷基、C1-6 烷氧基、C1-6 烷硫基、C2-7 烷酰基、羧基、C1-6 烷氧羰基、氰基的取代基取代; CONR7R8 其中 R7 和 R8 选自氢或 C1-6 烷基,或共同组成基团 X;NR9 R10,其中 R9 和 R10 选自氢、C1-6 烷基、C2-7 烷酰基或 C1-6 烷基磺酰基,或两者同为一个基团 X; SO2NR11R12,其中 R11 和 R12 选自氢或 C1-6 烷基,或两者同为一个基团 X;或 S(O)mR13 其中 m 为 1 或 2,R13 为 C1-6 烷基; Z 为萘基或单环或融合环状杂芳香族环,其芳香环中最多有 10 个原子,其中不超过 4 个原子选自氮、氧或硫,或(当 R3 为任选取代的萘基或定义的杂芳香族基团时)Z 为茚基环;Z任选被一个或两个取代基 R4 和 R5 取代,这两个取代基独立地选自 C1-6 烷基、氰基、氨基、氨基羰基或氨基甲酰基,任选被一个或两个 C1-6 烷基或基团 X、卤素、CF3、硝基、C1-6 烷氧基、C1-6 烷硫基、C2-7 烷酰氧基或羟基取代,或在相邻碳原子上一起被亚甲基二氧基或 C3-5 聚亚甲基取代。
  • US4745115A
    申请人:——
    公开号:US4745115A
    公开(公告)日:1988-05-17
  • Hunter, David J.; Markwell, Roger E.; Smith, Stephen A., Journal of the Chemical Society. Perkin transactions I, 1994, # 18, p. 2585 - 2590
    作者:Hunter, David J.、Markwell, Roger E.、Smith, Stephen A.、Wyman, Paul A.
    DOI:——
    日期:——
查看更多